OMERS Life Sciences’ $200 Million Acquisition of Portion of Global Royalties on MAVYRE

Martina Bellini
Tagged:

Ballard Spahr represented OMERS Life Sciences on the deal. Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

…

This content is for Standard 1 Year members only.
Login Join Now